AGR2 protein expression may support the histologic subtyping of nonsmall-cell lung cancer and be of clinical value in differentiating lung AdC from SCC.

Positive serum AGR2 expression in patients with lung adenocarcinoma was significantly associated with the incidence of recurrence after surgery and with a poor prognosis for overall survival

AGR2-mediated lung adenocarcinoma metastasis novel mechanism network through repression with interferon coupling cytoskeleton to steroid metabolism-dependent humoral immune response.

Nearly all NSCLC tumors show AGR2 expression. lung cancer expression of AGR2 has prognostic value for younger patients.

Authors demonstrated that inhibition of either FOXM1 or AGR2 in human PIMAs inhibited mucinous characteristics, and reduced tumor growth and invasion. FOXM1 is necessary and sufficient to induce mucinous phenotypes in lung tumor cells in vivo.

Modulation of overexpression of AGR2 in mutant non-small cell lung cancer cells may be an attractive therapeutic strategy for the treatment of EGFR-TKI-resistant non-small cell lung cancer.